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Abstract A patient who underwent fertility-sparing sur-
gery for Stage IA clear cell carcinoma may have developed
de novo clear cell carcinoma in the contralateral ovary
9 years later. She underwent fertility-sparing surgery and
postoperative adjuvant chemotherapy for right ovarian
carcinoma at 33 years of age (when endometriosis was
observed in the contralateral ovary). At the age of 41 years,
a tumor was discovered in the left ovary. This was diag-
nosed pathologically as clear cell carcinoma with clear cell
adenofibroma, which may have developed de novo. A
consensus is currently taking shape that although fertility-
sparing surgery is a therapeutic option for patients with
Stage IA clear cell carcinoma, long-term outpatient moni-
toring is advised to watch for its recurrence or de novo
development in the contralateral ovary.
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Introduction
We encountered a patient who had previously undergone
fertility-sparing surgery (FSS) for Stage IA clear cell car-
cinoma (CCC) 9 years earlier and again developed CCC in
the contralateral ovary, which was believed to be either de
novo or a recurrence. According to previous reports, cases
of recurrence of CCC usually occur within 1 year of the
primary tumor [1, 2], and there are no reports of recurrence
or de novo development after this much-extended period.
Our report highlights the need for long-term monitoring of
patients who undergo FSS. In our case, since clear cell
adenofibroma was a component of the second CCC, we
considered the possibility of de novo development. Our
case report discusses this point and presents a review of
similar cases presented in previous literature.
Since 2010, studies [3–5] have found that FSS may be
recommended for Stage IA CCC patients if suitable staging
and postoperative chemotherapy are performed, and a
consensus regarding this is gradually taking shape [6, 7]. In
Japan, the number of patients with epithelial ovarian cancer
(EOC) has been increasing in recent years, and in 2012,
6.8% of patients with this condition had developed it
before they reached the age of 40 years [8]. A consequence
of the standard treatment for CCC is infertility, but since
women today are marrying and having children at a later
age, an increasing number of patients are requesting
treatment that spares their fertility. Hence, the number of
Stage IA CCC patients who undergo FSS is likely to
increase.
Case report
Eleven years ago, when our patient was a 33-year-old
unmarried nulligravida, she developed CCC of the ovary
for the first time. At that time, her menstrual cycle was
regular and 30 days long, with dysmenorrhea, manifesting
as lower abdominal and lumbar pain, persisting for
5–7 days. There was no family or medical history of note.
She had visited a local clinic with the chief complaint of
lumbar pain, where a right ovarian tumor 8 cm in size that
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included solid internal components, was identified, and she
was referred to the University of Tsukuba Hospital.
Transvaginal ultrasound had revealed a right adnexal mass
with solid components, 68 mm 9 53 mm in size, and an
intramural uterine fibroid 23 mm 9 27 mm, with no
hypertrophy of the endometrium, which measured 2.1 mm.
Blood counts and blood biochemistry test results revealed
no abnormalities. Her serum CA19-9 level was 45.9 U/ml,
CA125 was 22 U/ml, and CEA level was 1.3 ng/ml.
Abdominal computed tomography (CT) and magnetic
resonance imaging (MRI) revealed an 80-mm unilocular
cystic mass in the right ovary with a papillary protrusion of
longest diameter 45 mm. The left ovary was not enlarged,
and there was no obvious peritoneal dissemination or
enlarged lymph nodes. Surgery, comprising right adnex-
ectomy, left ovarian biopsy, partial omentectomy and
uterine fibroid removal, was performed. The right ovary
was enlarged to 8 cm in size, and it was removed without
intraoperative rupture and with its capsule intact. The left
ovary was not enlarged, but was seen to have a small
endometrial cyst, which was resected. The absence of
peritoneal dissemination and enlarged lymph nodes was
confirmed during surgery. The pathological diagnosis was
CCC localized to the right ovary and endometriosis was
observed in the left ovary, with ascites cytology Class III.
The cytology was composed of clusters that include atyp-
ical cells having somewhat nuclear enlargement, and it
makes a diagnosis difficult to distinguish mesothelial cells
from malignant cells. The patient expressed a strong desire
to preserve her fertility. Hence, pelvic and para-aortic
lymph node dissections were performed via staged
laparotomy, which revealed no metastases in any of the 91
pelvic or para-aortic lymph nodes that were removed,
leading to a diagnosis of Stage IA CCC. Four courses of
postoperative combination paclitaxel (175 mg/m2) and
carboplatin (AUC6) chemotherapy (TC therapy) were
administered to complete the initial treatment.
Nine years after the initial therapy, MRI during regular
6-monthly monitoring revealed the appearance of a 95-mm
polycystic mass with a mural nodule of longest diameter
53 mm in the left adnexal region. Those findings were
never seen at the previous MRI. At this time, her serum
CA19-9 level was 12.9 U/ml, CA125 was 18.3 U/ml, and
CEA level was 0.5 ng/ml, all of which were within normal
limits. Disease recurrence in the contralateral ovary was
diagnosed, and total abdominal hysterectomy, left adnex-
ectomy and omental biopsy were performed. At the time of
surgery, the left ovary was enlarged to 95 mm in size, and
it was removed intact without intraoperative rupture of its
capsule. The internal lumen of the tumor contained several
milky-white mural nodules extending around 15 mm into
the cavity (Fig. 1). The histological diagnosis was CCC,
but in addition to the possibility of recurrence, it was also
considered that the tumor might have developed de novo,
and the fact that clear cell adenofibroma (CCAF) was also
present (Fig. 2) suggested that this might have provided the
genesis for its development. In addition, there were no
endometriotic lesions in the non-solid cyst wall, and it only
consists of fibrous membrane. The tumor was localized to
the left ovary, and since ascites cytology was negative, it
was diagnosed as Stage IA disease. The treatment was
completed with four courses of postoperative TC therapy.
Fig. 1 The resected ovarian
tumor enlarged to 95 mm in
size. The internal lumen of the
tumor contained several milky-
white mural nodules (right
arrow) extending around
15 mm into the cavity
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Two years after the completion of treatment, the patient
is continuing outpatient monitoring with no sign of recur-
rence to date.
Discussion
In an analysis of 211 EOC Stage I patients who underwent
FSS in Japan, none of the 15 patients with stage IA CCC
experienced recurrence, indicating that FSS is possibly a
feasible treatment option for these patients [3]; further, the
general opinion is that with careful patient selection, FSS is
a good treatment option for CCC patients [9]. In the present
case, 9 years after FSS, CCC developed in the contralateral
ovary. In all five previously reported confirmed cases of
recurrence following FSS for Stage IA CCC, [1, 2, 5, 10]
recurrence occurred within 1 year, and four of the five
lesions were present outside the contralateral ovary
(Table 1). The recurrence in the present case was extre-
mely delayed, suggesting the possibility of de novo
development from endometriosis of the contralateral ovary
at the time of initial surgery. A route of carcinogenesis that
does not involve endometriosis has also been suggested, in
which CCAF, a benign tumor, develops into CCC via
borderline malignant CCAF (atypical cells in the epithelial
component of CCAF) [11]. In our case, CCAF was found
in specimens of the ovarian tumor removed during left
adnexectomy at the time of the second tumor, and it is
possible that this was the site that gave rise to de novo
carcinoma. The median time to recurrence at a site other
than the contralateral ovary is reportedly 14 months (range
1–73 months), whereas for patients with recurrence only in
the contralateral ovary, this time is reportedly longer, at
43 months (range 2–172 months) [12], suggesting that the
latter group may have included some patients with de novo
carcinoma, as in the present case.
Mortality among patients with recurrence at a site other
than the contralateral ovary after FSS for ovarian carci-
noma has been reported to be 62 or 82%, compared with
only 13 or 19% for those who develop recurrence only in
the contralateral ovary, which is a considerably better
figure [12, 13]. We added data to those reports from other
studies which were not sited in them that clearly stated the
association between the site of recurrence and prognosis,
and we have summarized this data in Table 2, including the
proportion of patients surviving with no evidence of dis-
ease (NED) after salvage therapy for each site of
Fig. 2 Clear cell adenofibroma
(CCAF), transition of CCAF to
clear cell carcinoma (CCC) and
CCC components in the left
ovarian tumor at the patient’s
second treatment (HE 9200)
Table 1 Time to recurrence of patients with recurrence in stage IA
clear cell carcinoma
Author Year n TTR (months) Site of recurrence Status
Morice [1] 2005 1 6 Extra-ovary AWD
Park [2] 2008 2 11 Extra-ovary DOD
9 Extra-ovary AWD
Fruscio [5] 2013 1 8 Extra-ovary NED
Ditto [10] 2014 1 7 Residual ovary NED
TTR time to recurrence, NED no evidence of disease, AWD alive with
disease, DOD died of disease
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recurrence. Since the figures are simple calculations from
studies that differ in aspects such as monitoring periods,
they cannot be described as highly reliable, but they do
show a better prognosis for patients with recurrence in the
contralateral ovary alone, 75.9% of whom exhibited NED,
compared with a NED rate of only 16.7% in those with
recurrence at a site other than the contralateral ovary.
The present patient was enrolled in a retrospective study
[3] that found that not one of the 15 patients with Stage IA
CCC experienced recurrence, and her lesion in the left
ovary appeared after that paper was published. According
to previous reports, the patients with Stage IA CCC who
underwent FSS developed recurrence in about 1 year
[1, 2]; hence, ours is the first report of appearance of a
lesion 9 years after FSS. Ultimately, whether it represented
recurrence or de novo development remains unknown, but
in either case, the fact that salvage therapy alone after the
appearance of a lesion in the contralateral ovary offers the
prospect of a good prognosis indicates that patients who
have undergone FSS must be monitored carefully over the
long term, so that salvage therapy can be initiated while the
lesion is still restricted to the contralateral ovary.
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